# Immatics N.V. Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immatics-n-v - Industry: Biotechnology - Headquarters: Tuebingen, Germany - Website: www.immatics.com - Total disclosed funding: $237M - Latest round: Series E (Jun 28, 2017) - Investors on record: 17 ## About Immatics N.V., based in Tuebingen, Germany, is a biotechnology company developing innovative cancer immunotherapies that specifically engage T cells to combat tumors, utilizing proprietary technologies for targeted treatments.Immatics N.V. specializes in creating novel cancer immunotherapies, focusing on T Cell Receptor Therapy (TCR-T) and TCR Bispecifics. Founded in 2000 in Tuebingen, Germany, the company underwent a merger with Arya Sciences Acquisition Corp. in July 2020, significantly enhancing its operational scope. The company has completed 15 deals in total, with its most recent funding round, a PIPE, raising USD 35.00 mn on October 10, 2022, bringing the total amount raised to USD 35.00 mn. The company is led by CEOs Bernd Löffler and Harpreet Singh.Immatics specializes in the development of innovative cancer immunotherapies, utilizing its proprietary technologies to create targeted treatments aimed at engaging T cells against tumor cells. The company's primary product offerings include TCR-T (T Cell Receptor Therapy) and TCR Bispecifics, designed to recognize and attack cancerous cells. These therapies leverage Immatics' XPRESIDENT® technology to identify true tumor targets, facilitating a precise immune response for patients suffering from various cancers, particularly those expressing the PRAME target found in over 50 malignancies. The company serves a global clientele, partnering with leading pharmaceutical corporations and academic institutions, primarily focusing on North America and Europe, targeting patients diagnosed with solid tumors.In 2021, Immatics reported a revenue of USD 41.12 mn, alongside an EBITDA of USD -95.86 mn. The company generates revenue through strategic partnerships and collaborations in the biopharmaceutical sector, focusing on the development of its advanced immunotherapies. Revenue streams are structured around milestone payments and potential royalties from product sales, following successful commercialization of their therapies, with pricing established through agreements reflecting the innovative nature of their offerings.Looking ahead, Immatics N.V. plans to expand its product offerings, focusing on the development of additional immunotherapy solutions to address unmet needs in oncology. The company targets expansion into North American and European markets, with specific timelines yet to be defined. The recent funding from the PIPE deal will bolster these initiatives, supporting the company's growth strategy and operational advancements following the merger with Arya Sciences Acquisition Corp. As part of its growth strategy, Immatics aims to leverage its technologies to enhance its therapeutic pipeline and establish stronger partnerships in the pharmaceutical industry. ## Funding rounds - Series E, Jun 28, 2017, $58M — Wellington Partners, EMBL Ventures, KfW Banking Group, Palmetto Partners, Merifin Capital, Amgen Ventures, Grazia Equity, Dievini, MIG Capital, AT Impf GmbH, Kuwait Life Sciences Company - Series D, Jul 25, 2014, $30M — Wellington Partners, EMBL Ventures, Merifin Capital, Grazia Equity, Dievini, AT Impf GmbH - Series D, Oct 7, 2013, $16M — Wellington Partners, EMBL Ventures, KfW Banking Group, Merifin Capital, National Technology Enterprises Company, Grazia Equity, Dievini, MIG Capital, AT Impf GmbH - Series C, Sep 7, 2010, $69M — Wellington Partners, EMBL Ventures, KfW Banking Group, Merifin Capital, National Technology Enterprises Company, Grazia Equity, Dievini, MIG Capital, AT Impf GmbH - Series B, Feb 19, 2007, $54M — 3i, Wellington Partners, EMBL Ventures, KfW Banking Group, Landesbank Baden-Württemberg, Merifin Capital, National Technology Enterprises Company, Grazia Equity, OH Beteiligungen GmbH, LEA Partners, DH Capital GmbH & Co. - Series A, Apr 28, 2004, $0.6M — EMBL Ventures - Series A, Feb 11, 2004, $9.8M — 3i, Wellington Partners, Merifin Capital, Grazia Equity, LEA Partners ## Investors - 3i (https://capitalatlas.ai/funds/3i) — Series A, Series B - Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series A, Series B, Series C, Series D, Series E - Merifin Capital (https://capitalatlas.ai/funds/merifin-capital) — Series A, Series B, Series C, Series D, Series E - Grazia Equity (https://capitalatlas.ai/funds/grazia-equity) — Series A, Series B, Series C, Series D, Series E - LEA Partners (https://capitalatlas.ai/funds/lea-partners) — Series A, Series B - EMBL Ventures (https://capitalatlas.ai/funds/embl-ventures) — Series A, Series B, Series C, Series D, Series E - KfW Banking Group — Series B, Series C, Series D, Series E - Landesbank Baden-Württemberg — Series B - National Technology Enterprises Company — Series B, Series C, Series D - OH Beteiligungen GmbH — Series B - DH Capital GmbH & Co. — Series B - Dievini (https://capitalatlas.ai/funds/dievini) — Series C, Series D, Series E - MIG Capital (https://capitalatlas.ai/funds/mig-capital) — Series C, Series D, Series E - AT Impf GmbH — Series C, Series D, Series E - Palmetto Partners — Series E - Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series E - Kuwait Life Sciences Company (https://capitalatlas.ai/funds/kuwait-life-sciences-company) — Series E